137973-76-3 Usage
Description
N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide is a complex organic compound with a molecular structure characterized by a benzamide core, a chlorinated benzazepin moiety, and methyl groups attached to the phenyl rings. N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide is likely to have specific applications in various industries due to its unique chemical properties.
Uses
Used in Pharmaceutical Industry:
N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide is used as an active pharmaceutical ingredient for the treatment of various medical conditions. Its specific application reason is due to its interaction with biological targets, such as receptors or enzymes, which can modulate physiological processes and provide therapeutic benefits.
Used in Chemical Research:
In the field of chemical research, N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide can be used as a starting material or a synthetic intermediate for the development of new compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Drug Synthesis:
N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide is used as a key intermediate in the synthesis of various drugs, particularly those targeting the central nervous system or cardiovascular system. Its application reason is based on its structural similarity to known pharmacophores and its potential to be modified to improve drug efficacy, safety, or pharmacokinetic properties.
Note: The provided materials do not contain specific information about the uses of N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide. The uses listed above are hypothetical and based on the general properties and applications of similar compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 137973-76-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,7,9,7 and 3 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 137973-76:
(8*1)+(7*3)+(6*7)+(5*9)+(4*7)+(3*3)+(2*7)+(1*6)=173
173 % 10 = 3
So 137973-76-3 is a valid CAS Registry Number.
137973-76-3Relevant articles and documents
Efficient and promising asymmetric preparation of enantiopure tolvaptan via transfer hydrogenation with robust catalysts
Yin, Lu,Zheng, Yourou,Jia, Xian,Li, Xingshu,Chan, Albert S.C.
, p. 2390 - 2393 (2010)
Enantiopure tolvaptan, the first and only oral vasopressin antagonist for hyponatremia has been prepared by using an asymmetric transfer hydrogenation as a key step with HCOOH-Et3N or HCOONa-H2O as the hydrogen donor in open air. Good chemical yields with up to 99% enantioselectivity were obtained with a 1000:1 of S/C in an HCOONa-H2O system. The air and water stable catalysts provide a very promising prospect for industrial application.
INTERMEDIATES AND METHODS FOR THE PREPARATION OF TOLVAPTAN AND ITS DERIVATIVES
-
, (2021/12/31)
The present invention relates to new intermediates for the synthesis of tolvaptan and its derivatives, as well as a method for its preparation involving said intermediates.
Novel benzoazepine compound, composition and applications of novel benzoazepine compound and composition
-
Paragraph 0135-0141, (2021/05/29)
The invention relates to a novel benzoazepine compound, which comprises a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition containing the compound and the pharmaceutically acceptable salt thereof. The pres
Method for preparing high-purity tolvaptan intermediate
-
, (2018/10/02)
The invention provides a method for preparing a high-purity tolvaptan intermediate, and concretely provides a method for purifying a tolvaptan intermediate N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-oxo-1H-1-benzazepine-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide (formula II). A crude product containing the compound of formula II is recrystallized by an organic solvent composed of ester, haloalkaneand ether to preferably obtain the compound of formula II, having a purity of above 99.00%.